Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's repeatable business is escalating. We need to look for management's own words that compare current deals/orders/projects to past ones, showing that each new instance is bigger, broader, or longer. Let's scan the transcript. The call covers Adaptive Biotechnologies, with MRD (clonoSEQ) and Immune Medicine segments. Management discusses growth in volumes, revenue, etc. But we need to find if they mention that the size of individual deals, contracts, or engagements is increasing. Key points: In MRD, they talk about test volumes growing, ASP increasing, more accounts, more patients. But that's volume and price, not necessarily larger individual engagements. They mention community business growing from 8% to 15% of total, but that's mix, not size per engagement. In Immune Medicine, they talk about pharma services growth, but not about individual deal sizes. They mention Genentech partnership, but that's a single large partnership, not a pattern of escalating deal sizes. They mention milestones, but those are one-time events. The question specifically asks about "successive engagements of the same kind" coming in at "progressively larger size." For example, new orders being bigger than before, customers starting at higher levels, etc. I don't see any such statement. Management talks about growth in volumes, revenue, ASP, but not about the size of individual contracts or deals increasing. They talk about expanding into new indications like DLBCL, but that's a new market, not necessarily larger engagements. They also mention "record high" orders in the past month, but that could be volume, not size per order. The question requires a comparison against the company's own recent past for the same offering. I don't see that. Thus, the answer is NO. We need to be careful: The question says "Answer YES when management's own words convey... the unit size of the company's own repeatable business is escalating." There is no such expression. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.